Prot# ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Severe RSV Illness

Project: Research project

Project Details

StatusFinished
Effective start/end date8/18/088/18/11

Funding

  • ADMA Biologics, Inc. (ADMA-001)